Floatz logo

L-Kappa-H-Gamma1 (Knob) Chain Anti-Dll3 (1-705) [L-Kappa Anti-Dll3 (1-214) [V-Kappa (Homo Sapiens Igkv1-17*03 (94.9%) -Igkj2*01 (100%), Cdr-Imgt [6.3.9] (27-32.50-52.89-97)) (1-107) -Homo Sapiens Igkc*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')] -38-Mer (Ggggse Gkssgsgses Kstegkssgs Gseskstggggs) Linker (215-252) -H-Gamma-1 Heavy Chain Anti-Dll3 (253-705) [Vh (Homo Sapiens Ighv1-46*01 (92.9%) -(Ighd) -Ighj6*01 (94.7%), Cdr-Imgt [8.8.17] (278-285.303-310.349-365)) (253-376)-Homo Sapiens Ighg1*03, G1M3, Ng1M1, Ch1 R120, Ch3 E12, M14, G1V14 Ch2 A1.3, A1.2, G1V32 Ch3 W22 (Knob) (Ch1 R120 (473) (377-474), Hinge 1-15 (475-489), Ch2 L1.3>A (493), L1.2>A (494) (490-599), Ch3 E12 (615), M14 (617), T22>W (625) (600-704), Chs K2>Del (705)) (377-705)]]; L-Lambda6-H-Gamma1 (Hole) Chain Anti-Cd3E (1-707) [L-Lambda6 Anti-Cd3 (1'-215') [V-Lambda Musmus/Homsap (Mus Musculus Iglv1*01 (82.3%) -Iglj1*01 (100%)/Homo Sapiens Iglv7-46*01 (76.8%) -Iglj3*02 (100%), Cdr-Imgt [9.3.9] (26'-34'.52'-54'.91'-99')) (1'-109') -Homo Sapiens Iglc6*01 (100%) (110'-215')] -38-Mer (Ggggse Gkssgsgses Kstegkssgsgseskstggggs) Linker (216'-253') -H-Gamma-1 Anti-Cd3E (254'-707') [Vh Musmus/Homsap (Mus Musculus Ighv10-1*02 (92.9%) -(Ighd) -Ighj3*01 (100%)/Homo Sapiens Ighv3-73*01 (87.0%) -(Ighd) -Ighj6*01 (81.8%) T123>L (373'), S128>A (378'), Cdr-Imgt [8.10.16] (279'-286'.304'-313'.352'-367')) (254'-378')-Homo Sapiens Ighg1*03, G1M3, Ng1M1, Ch1 R120, Ch3 E12, M14, G1V14 Ch2 A1.3, A1.2, G1V33 Ch3 S22, A24, V86 (Hole), G1V83 Ch3 R115, F116 (Ch1 R120 (475') (379'-476'), Hinge 1-15 (477'-491'), Ch2 L1.3>A (495'), L1.2>A (496') (492'-601'), Ch3 E12 (617'), M14 (619'), T22>S (627'), L24>A (629'), Y86>V (686'), H115>R (696'), Y116>F (697') (602'-706'), Chs K2>Del (707')) (379'-707')]]; Dimer (485-487':488-490')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1, Glycoform Alfa

Neuroendocrine Carcinoma

Explore 48 assets in Neuroendocrine Carcinoma →
Floatz Rating
CCC53/100
Confidence
Indicative
v0.2
Sponsor
Boehringer Ingelheim
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT05882058CT.gov
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
—Recruiting———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Neuroendocrine Carcinoma

AssetSponsorPhaseRating
L-Kappa-H-Gamma1 (Knob) Chain Anti-Dll3 (1-705) [L-Kappa Anti-Dll3 (1-214) [V-Kappa (Homo Sapiens Igkv1-17*03 (94.9%) -Igkj2*01 (100%), Cdr-Imgt [6.3.9] (27-32.50-52.89-97)) (1-107) -Homo Sapiens Igkc*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')] -38-Mer (Ggggse Gkssgsgses Kstegkssgs Gseskstggggs) Linker (215-252) -H-Gamma-1 Heavy Chain Anti-Dll3 (253-705) [Vh (Homo Sapiens Ighv1-46*01 (92.9%) -(Ighd) -Ighj6*01 (94.7%), Cdr-Imgt [8.8.17] (278-285.303-310.349-365)) (253-376)-Homo Sapiens Ighg1*03, G1M3, Ng1M1, Ch1 R120, Ch3 E12, M14, G1V14 Ch2 A1.3, A1.2, G1V32 Ch3 W22 (Knob) (Ch1 R120 (473) (377-474), Hinge 1-15 (475-489), Ch2 L1.3>A (493), L1.2>A (494) (490-599), Ch3 E12 (615), M14 (617), T22>W (625) (600-704), Chs K2>Del (705)) (377-705)]]; L-Lambda6-H-Gamma1 (Hole) Chain Anti-Cd3E (1-707) [L-Lambda6 Anti-Cd3 (1'-215') [V-Lambda Musmus/Homsap (Mus Musculus Iglv1*01 (82.3%) -Iglj1*01 (100%)/Homo Sapiens Iglv7-46*01 (76.8%) -Iglj3*02 (100%), Cdr-Imgt [9.3.9] (26'-34'.52'-54'.91'-99')) (1'-109') -Homo Sapiens Iglc6*01 (100%) (110'-215')] -38-Mer (Ggggse Gkssgsgses Kstegkssgsgseskstggggs) Linker (216'-253') -H-Gamma-1 Anti-Cd3E (254'-707') [Vh Musmus/Homsap (Mus Musculus Ighv10-1*02 (92.9%) -(Ighd) -Ighj3*01 (100%)/Homo Sapiens Ighv3-73*01 (87.0%) -(Ighd) -Ighj6*01 (81.8%) T123>L (373'), S128>A (378'), Cdr-Imgt [8.10.16] (279'-286'.304'-313'.352'-367')) (254'-378')-Homo Sapiens Ighg1*03, G1M3, Ng1M1, Ch1 R120, Ch3 E12, M14, G1V14 Ch2 A1.3, A1.2, G1V33 Ch3 S22, A24, V86 (Hole), G1V83 Ch3 R115, F116 (Ch1 R120 (475') (379'-476'), Hinge 1-15 (477'-491'), Ch2 L1.3>A (495'), L1.2>A (496') (492'-601'), Ch3 E12 (617'), M14 (619'), T22>S (627'), L24>A (629'), Y86>V (686'), H115>R (696'), Y116>F (697') (602'-706'), Chs K2>Del (707')) (379'-707')]]; Dimer (485-487':488-490')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1, Glycoform Alfa (this asset)Boehringer IngelheimP2CCC · 53
EtoposideNational Cancer Institute (NCI)P2B
EverolimusAIO-Studien-gGmbHP2B
L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R*,R*))-Novartis PharmaceuticalsP2B
LurbinectedinJazz PharmaceuticalsP2B
Cis-Diamminedichloroplatinum IiNational Cancer Institute (NCI)P2B
PembrolizumabOchsner Health SystemP2B
TarlatamabNational Cancer Institute (NCI)P2B
IpilimumabNational Cancer Institute (NCI)P2B

+42 more in the Neuroendocrine Carcinoma cohort

Other indications for L-Kappa-H-Gamma1 (Knob) Chain Anti-Dll3 (1-705) [L-Kappa Anti-Dll3 (1-214) [V-Kappa (Homo Sapiens Igkv1-17*03 (94.9%) -Igkj2*01 (100%), Cdr-Imgt [6.3.9] (27-32.50-52.89-97)) (1-107) -Homo Sapiens Igkc*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')] -38-Mer (Ggggse Gkssgsgses Kstegkssgs Gseskstggggs) Linker (215-252) -H-Gamma-1 Heavy Chain Anti-Dll3 (253-705) [Vh (Homo Sapiens Ighv1-46*01 (92.9%) -(Ighd) -Ighj6*01 (94.7%), Cdr-Imgt [8.8.17] (278-285.303-310.349-365)) (253-376)-Homo Sapiens Ighg1*03, G1M3, Ng1M1, Ch1 R120, Ch3 E12, M14, G1V14 Ch2 A1.3, A1.2, G1V32 Ch3 W22 (Knob) (Ch1 R120 (473) (377-474), Hinge 1-15 (475-489), Ch2 L1.3>A (493), L1.2>A (494) (490-599), Ch3 E12 (615), M14 (617), T22>W (625) (600-704), Chs K2>Del (705)) (377-705)]]; L-Lambda6-H-Gamma1 (Hole) Chain Anti-Cd3E (1-707) [L-Lambda6 Anti-Cd3 (1'-215') [V-Lambda Musmus/Homsap (Mus Musculus Iglv1*01 (82.3%) -Iglj1*01 (100%)/Homo Sapiens Iglv7-46*01 (76.8%) -Iglj3*02 (100%), Cdr-Imgt [9.3.9] (26'-34'.52'-54'.91'-99')) (1'-109') -Homo Sapiens Iglc6*01 (100%) (110'-215')] -38-Mer (Ggggse Gkssgsgses Kstegkssgsgseskstggggs) Linker (216'-253') -H-Gamma-1 Anti-Cd3E (254'-707') [Vh Musmus/Homsap (Mus Musculus Ighv10-1*02 (92.9%) -(Ighd) -Ighj3*01 (100%)/Homo Sapiens Ighv3-73*01 (87.0%) -(Ighd) -Ighj6*01 (81.8%) T123>L (373'), S128>A (378'), Cdr-Imgt [8.10.16] (279'-286'.304'-313'.352'-367')) (254'-378')-Homo Sapiens Ighg1*03, G1M3, Ng1M1, Ch1 R120, Ch3 E12, M14, G1V14 Ch2 A1.3, A1.2, G1V33 Ch3 S22, A24, V86 (Hole), G1V83 Ch3 R115, F116 (Ch1 R120 (475') (379'-476'), Hinge 1-15 (477'-491'), Ch2 L1.3>A (495'), L1.2>A (496') (492'-601'), Ch3 E12 (617'), M14 (619'), T22>S (627'), L24>A (629'), Y86>V (686'), H115>R (696'), Y116>F (697') (602'-706'), Chs K2>Del (707')) (379'-707')]]; Dimer (485-487':488-490')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1, Glycoform Alfa

IndicationSponsorPhaseRating
Small Cell Lung Carcinoma—P3BB · 70
Neuroendocrine Neoplasm—P2B · 60

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. L-Kappa-H-Gamma1 (Knob) Chain Anti-Dll3 (1-705) [L-Kappa Anti-Dll3 (1-214) [V-Kappa (Homo Sapiens Igkv1-17*03 (94.9%) -Igkj2*01 (100%), Cdr-Imgt [6.3.9] (27-32.50-52.89-97)) (1-107) -Homo Sapiens Igkc*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')] -38-Mer (Ggggse Gkssgsgses Kstegkssgs Gseskstggggs) Linker (215-252) -H-Gamma-1 Heavy Chain Anti-Dll3 (253-705) [Vh (Homo Sapiens Ighv1-46*01 (92.9%) -(Ighd) -Ighj6*01 (94.7%), Cdr-Imgt [8.8.17] (278-285.303-310.349-365)) (253-376)-Homo Sapiens Ighg1*03, G1M3, Ng1M1, Ch1 R120, Ch3 E12, M14, G1V14 Ch2 A1.3, A1.2, G1V32 Ch3 W22 (Knob) (Ch1 R120 (473) (377-474), Hinge 1-15 (475-489), Ch2 L1.3>A (493), L1.2>A (494) (490-599), Ch3 E12 (615), M14 (617), T22>W (625) (600-704), Chs K2>Del (705)) (377-705)]]; L-Lambda6-H-Gamma1 (Hole) Chain Anti-Cd3E (1-707) [L-Lambda6 Anti-Cd3 (1'-215') [V-Lambda Musmus/Homsap (Mus Musculus Iglv1*01 (82.3%) -Iglj1*01 (100%)/Homo Sapiens Iglv7-46*01 (76.8%) -Iglj3*02 (100%), Cdr-Imgt [9.3.9] (26'-34'.52'-54'.91'-99')) (1'-109') -Homo Sapiens Iglc6*01 (100%) (110'-215')] -38-Mer (Ggggse Gkssgsgses Kstegkssgsgseskstggggs) Linker (216'-253') -H-Gamma-1 Anti-Cd3E (254'-707') [Vh Musmus/Homsap (Mus Musculus Ighv10-1*02 (92.9%) -(Ighd) -Ighj3*01 (100%)/Homo Sapiens Ighv3-73*01 (87.0%) -(Ighd) -Ighj6*01 (81.8%) T123>L (373'), S128>A (378'), Cdr-Imgt [8.10.16] (279'-286'.304'-313'.352'-367')) (254'-378')-Homo Sapiens Ighg1*03, G1M3, Ng1M1, Ch1 R120, Ch3 E12, M14, G1V14 Ch2 A1.3, A1.2, G1V33 Ch3 S22, A24, V86 (Hole), G1V83 Ch3 R115, F116 (Ch1 R120 (475') (379'-476'), Hinge 1-15 (477'-491'), Ch2 L1.3>A (495'), L1.2>A (496') (492'-601'), Ch3 E12 (617'), M14 (619'), T22>S (627'), L24>A (629'), Y86>V (686'), H115>R (696'), Y116>F (697') (602'-706'), Chs K2>Del (707')) (379'-707')]]; Dimer (485-487':488-490')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1, Glycoform Alfa in Neuroendocrine Carcinoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/l-kappa-h-gamma1-knob-chain-anti-dll3-1-705-l-kappa-anti-dll3-1-214-v-kappa-homo-sapiens-igkv1-1703-949-igkj201-100-cdr-imgt-639-27-3250-5289-97-1-107-homo-sapiens-igkc01-100-km3-a451-153-v101-191-108-214-38-mer-ggggse-gkssgsgses-kstegkssgs-gseskstggggs-linker-215-252-h-gamma-1-heavy-chain-anti-dll3-253-705-vh-homo-sapiens-ighv1-4601-929-ighd-ighj601-947-cdr-imgt-8817-278-285303-310349-365-253-376-homo-sapiens-ighg103-g1m3-ng1m1-ch1-r120-ch3-e12-m14-g1v14-ch2-a13-a12-g1v32-ch3-w22-knob-ch1-r120-473-377-474-hinge-1-15-475-489-ch2-l13a-493-l12a-494-490-599-ch3-e12-615-m14-617-t22w-625-600-704-chs-k2del-705-377-705-l-lambda6-h-gamma1-hole-chain-anti-cd3e-1-707-l-lambda6-anti-cd3-1-215-v-lambda-musmushomsap-mus-musculus-iglv101-823-iglj101-100homo-sapiens-iglv7-4601-768-iglj302-100-cdr-imgt-939-26-3452-5491-99-1-109-homo-sapiens-iglc601-100-110-215-38-mer-ggggse-gkssgsgses-kstegkssgsgseskstggggs-linker-216-253-h-gamma-1-anti-cd3e-254-707-vh-musmushomsap-mus-musculus-ighv10-102-929-ighd-ighj301-100homo-sapiens-ighv3-7301-870-ighd-ighj601-818-t123l-373-s128a-378-cdr-imgt-81016-279-286304-313352-367-254-378-homo-sapiens-ighg103-g1m3-ng1m1-ch1-r120-ch3-e12-m14-g1v14-ch2-a13-a12-g1v33-ch3-s22-a24-v86-hole-g1v83-ch3-r115-f116-ch1-r120-475-379-476-hinge-1-15-477-491-ch2-l13a-495-l12a-496-492-601-ch3-e12-617-m14-619-t22s-627-l24a-629-y86v-686-h115r-696-y116f-697-602-706-chs-k2del-707-379-707-dimer-485-487488-490-bisdisulfide-produced-in-chinese-hamster-ovary-cho-cells-cell-line-cho-k1-glycoform-alfa-neuroendocrine-carcinoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →